A Phase 4 interventional study of Omalizumab in Food Allergy, sponsored by Johns Hopkins University. Recruiting at 1 site in United States. Open to participants aged 1 Year to 30 Years. Per ClinicalTrials.gov, last updated 2026-10-28.
Sponsored by Johns Hopkins University · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing omalizumab in Food Hypersensitivity — 4 open to participants now, 4 under way, none of them phase 3. Omalizumab · Food Hypersensitivity.
Among the 12 studies testing omalizumab in Food Hypersensitivity, this one is the 10th largest by planned enrollment, is the only one that started in 2026, is one of 5 in phase 4, and was the 12th registered.
378 studies on the registry are indexed under Food Hypersensitivity; 92 are open to participants now.
Browse Food Hypersensitivity studies →4 of the 12 studies testing omalizumab in Food Hypersensitivity are open now, in 1 country. Recruiting first, the newest first:
Massachusetts General Hospital · Sites in United States
Ages 1–55
Johns Hopkins University · Sites in United States
Ages 1–55
National Jewish Health · Sites in United States
Ages 1–55 · Healthy volunteers
By country, each count listing its studies:
Omalizumab: first FDA approval 2003 (XOLAIR), first EMA approval 2005. What it is approved for, and how studies give it, is on its page →
Of the 54 Food Hypersensitivity studies recruiting now, 8 (15%) set no upper age limit and 42 (78%) stop at 75 or younger; 46 take children under 18; 17 take healthy volunteers.
This study: 1 Year to 30 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, omalizumab is the treatment under test here. Read study by study →
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 7 · Phase 4 5
First in 2009; this study’s year is marked. 1 started in 2026.
This study's planned enrollment of 20 is below the median of 60 across 248 interventional studies indexed under Food Hypersensitivity.
Median enrollment 34 across the 12 interventional studies. Of the 8 that completed or were terminated, 5 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 12 has an industry lead sponsor. The 8 most frequent:
Johns Hopkins University is the lead sponsor of 1,816 studies on the registry; 315 are open to participants now.
Of its 208 completed or terminated interventional studies of FDA-regulated products, 144 (69%) have results posted.
11 studies in Food Hypersensitivity by Johns Hopkins University: 2 open now, 2 under way, none of them phase 3. Of 8 finished, 8 (100%) have results posted.
Among the 11 studies in Food Hypersensitivity by Johns Hopkins University, this one is the 7th largest by planned enrollment, is the only one that started in 2026, is the only one in phase 4, and was the 11th registered.
Johns Hopkins University’s Food Hypersensitivity studies by the year they started, since 2006.
2 of the studies testing omalizumab in Food Hypersensitivity that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06934200Johns Hopkins UniversityOmalizumab for the Treatment of Food Allergy in Patients With Elevated Total IgE Levels | 2027-04-15 |
| NCT06943534Massachusetts General HospitalOmalizumab Weight-Based Dosing Efficacy Trial | 2027-05-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 12 studies testing omalizumab in Food Hypersensitivity, from their registry updates:
Among Johns Hopkins University’s 11 in Food Hypersensitivity:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to learn how quickly omalizumab begins to work in people with food allergy. The main question it aims to answer is:
Researchers will compare each participant's food challenge results at baseline before starting omalizumab, 2 to 4 weeks after starting omalizumab, and 4 to 6 months after starting omalizumab treatment.
Participants will:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Omalizumab is approved by the FDA for the treatment of food allergy in patients aged 1 year and older. Omalizumab is administered as a subcutaneous injection at doses ranging from 75 mg to 600 mg every 2 or 4 weeks. Omalizumab treatment is not provided as part of this study. Participants will receive omalizumab treatment as part of their routine care for food allergy as prescribed by their doctor in the clinical setting.
Drug: Omalizumab
Prior to starting omalizumab, participants will undergo a baseline oral food challenge. Participants will then initiate omalizumab treatment as prescribed by their doctor as part of routine clinical care. After 2 to 4 weeks of treatment (following one to two doses of omalizumab), participants will undergo a first post-treatment oral food challenge to assess treatment response. After 4 to 6 months of omalizumab treatment, participants will undergo a second post-treatment oral food challenge. The study will conclude following the second post-treatment oral food challenge.
Proportion of participants achieving pre-specified thresholds without dose-limiting symptoms during first post-treatment oral food challenge.
The pre-specified thresholds for response is defined as the ability to consume at least two more incremental doses of food protein during post-treatment oral food challenge (using incremental doses of 3, 10, 30, 100, 300, 600, 1000, 2000, 2000, and 2000 mg), than during the baseline oral food challenge. First post-treatment oral food challenge conducted between ≥14 and ≤35 days after starting omalizumab (after one or two doses of omalizumab depending on whether the participant is receiving omalizumab every 2 or 4 weeks).
Time frame: Between ≥14 and ≤35 days after starting omalizumab
The absolute change in oral food challenge threshold between baseline and the first post-treatment oral food challenge.
Baseline oral food challenge conducted prior to starting omalizumab. First post-treatment oral food challenge conducted at ≥14 and ≤35 days after starting of omalizumab.
Time frame: Baseline, between ≥14 and ≤35 days after starting omalizumab
The absolute change in oral food challenge threshold between the first and second post-treatment oral food challenges.
First post-treatment oral food challenge conducted at ≥14 and ≤35 days after starting of omalizumab. Second post-treatment oral food challenge conducted between 4 to 6 months after starting omalizumab.
Time frame: between ≥14 and ≤35 days after starting omalizumab, 4-6 months after starting omalizumab
Correlation between oral food challenge threshold and biomarkers including skin prick testing, allergen-specific IgE, total IgE, and free total IgE.
Oral food challenge threshold measures the amount of food protein (mg) consumed without dose-limiting symptoms. Biomarkers include skin prick test measured by wheal diameter (mm), allergen-specific IgE concentration (kUA/L), total IgE concentration (IU/mL), and free total IgE concentration (IU/mL).
Time frame: At baseline, between ≥14 and ≤35 days starting omalizumab, and 4 to 6 months after starting omalizumab
Plan to share: No — There are no plans to share individual participant data.
No publications or documents are linked to this record.
Started Oct 2026 (actual). Primary completion is estimated for Oct 2028, 24 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Omalizumab